Persistence of Gadolinium in CSF: A Diagnostic Pitfall in Patients with End-stage Renal Disease

References

1. ↵
   Staks T, Schuhmann-Giampieri G, Frenzel T, Weinmann HJ, Lange L, Platzek J. Pharmacokinetics, dose proportionality, and tolerability of gadobutrol after single intravenous injection in healthy volunteers. Invest Radiol 1994;29:709-715

   CrossRefPubMedWeb of Science
2. ↵
   Joffe P, Thomsen HS, Meusel M. Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol 1998;5:491-502

   CrossRefPubMedWeb of Science
3. ↵
   Tombach B, Bremer C, Reimer P, Schaefer RM, Ebert W, Geens V, Heindel W. Pharmacokinetics of 1M gadobutrol in patients with chronic renal failure. Invest Radiol 2000;35:35-40

   CrossRefPubMedWeb of Science
4. Swan SK, Baker JF, Free R, et al. Pharmacokinetics, safety, and tolerability of gadoversetamide injection (OptiMARK) in subjects with central nervous system or liver pathology and varying degrees of renal function. J Magn Reson Imaging 1999;9:317-321

   CrossRefPubMed
5. Schuhmann-Giampieri G, Krestin G. Pharmacokinetics of Gd-DTPA in patients with chronic renal failure. Invest Radiol 1991;26:975-979

   PubMedWeb of Science
6. ↵
   Choyke PL, Girton ME, Vaughan EM, et al. Clearance of gadolinium chelates by hemodialysis: an in vitro study. J Magn Reson Imaging 1995;5:470-472

   PubMed
7. ↵
   Katagiri K, Okada S, Kumazaki T, Tsuboi N. Clearance of gadolinium contrast agent by hemodialysis: in vitro and clinical studies. Nippon Igaku Hoshasen Gakkai Zasshi 1998;58:739-744

   PubMed
8. ↵
   Melhem ER, Jara H, Eustace S. Fluid-attenuated inversion recovery MR imaging: identification of protein concentration thresholds for CSF hyperintensity. AJR Am J Roentgenol 1997;169:859-862

   CrossRefPubMedWeb of Science
9. ↵
   Eckel TS, Breiter SN, Monsein LH. Subarachnoid contrast enhancement after spinal angiography mimicking diffuse subarachnoid hemorrhage. AJR Am J Roentgenol 1998;170:503-505

   CrossRefPubMedWeb of Science
10. ↵
    Dechambre SD, Duprez T, Grandin CB, Lecouvet FE, Peeters A, Cosnard G. High signal in cerebrospinal fluid mimicking subarachnoid hemorrhage on FLAIR following acute stroke and intravenous contrast medium. Neuroradiology 2000;42:608-611

    CrossRefPubMed
11. ↵
    Davson H. Dynamic aspects of cerebrospinal fluid. Dev Med Child Neurol (Suppl) 1972;27:1-16
12. ↵
    Carpenter MB. Core Text of Neuroanatomy, (3rd ed). Baltimore: Williams & Wilkins; 1985:1–19
13. ↵
    Bering EA Jr. The cerebrospinal fluid and the extracellular fluid of the brain. Introductory remarks. Fed Proc 1974;33:2061-2066

    PubMed
14. Sharp S, Stone J, Beach R. Contrast agent neurotoxicity presenting as subarachnoid hemorrhage. Neurology 1999;52:1503-1505

    Abstract/FREE Full Text
15. ↵
    Knutzon RK, Poirer VC, Gerscovich EO, Brock JM, Buonocore M. The effect of intravenous gadolinium on the magnetic resonance appearance of cerebrospinal fluid. Invest Radiol 1991;26:671-673

    CrossRefPubMed
16. ↵
    Stone JA, Sharp S, Castillo M. Subarachnoid contrast enhancement mimicking subarachnoid hemorrhage after coronary angiography. AJR Am J Roentgenol 1999;831–832
17. Mamourian AC, Hoopes PJ, Lewis LD. Visualization of intravenously administered contrast material in the CSF on fluid-attenuated inversion-recovery MR images: an in vitro and animal-model investigation. AJNR Am J Neuroradiol 2000;21:105-111

    Abstract/FREE Full Text
18. Mathews VP, Caldemeyer KS, Lowe MJ, Greenspan SL, Weber DM, Ulmer JL. Brain: gadolinium-enhanced fast fluid-attenuated inversion-recovery MR imaging [see comments]. Radiology 1999;211:257-263

    PubMed
19. ↵
    Lev MH, Schaefer PW. Subarachnoid gadolinium enhancement mimicking subarachnoid hemorrhage on FLAIR MR images. Fluid attenuated inversion recovery (letter). AJR Am J Roentgenol 1999;173:1414-1415

    PubMed